Phaseline

Targets › MC4R

MC4R (Melanocortin receptor 4): drug programs, companies and trials

3 programs from 2 companies in 6 trials: 2 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4; Metabolic and endocrine; next expected readout Mar 2027.

G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha- and beta-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor. Functions as a central component of the leptin-melanocortin pathway, which is essential for maintaining energy homeostasis. (UniProt, P32245)

Open in Phaseline: the race on MC4R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rhythm PharmaceuticalsSetmelanotide
Melanocortin receptor 4 agonist
MC4RPhase 3Hypothalamic Obesity; Prader-Willi Syndrome; Bardet Biedl Syndrome (BBS)Mar 2027
Palatin Technologiesbremelanotide
Melanocortin receptor 4 agonist
MC4RPhase 2Obesity–
Rhythm PharmaceuticalsRM-718
MC4R (melanocortin 4 receptor) agonist
MC4RPhase 1Hypothalamic ObesityMay 2027

Conditions

Hypothalamic Obesity (3) Obesity (1) Prader-Willi Syndrome (1) Bardet Biedl Syndrome (BBS) (1)

Modalities

protein or peptide (2), small molecule (1)

Companies

Rhythm Pharmaceuticals (2) Palatin Technologies (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.